All News

CDMO to invest in its facility in Hlohovec, Slovakia, to increase the scale at which it can perform wurster coating of the pellets.

Screening method provides a potential new approach to repurpose known drugs and compounds.

Research has shown that boosting immunity in the nose and lungs may be the best way of increasing defence against RSV.

Currently, there is no available drug that can treat the negative symptoms of schizophrenia, according to GlobalData.

Biologics and monoclonal antibodies to become a bigger presence within the small-molecule-dominated landscape.

Company's focus on low-volume, niche pharmaceutical products is meeting a largely unmet need in the industry at a global level.

GlobalData anticipates ALKS-5461 will enter the US market in early 2018.

Potential to be first submission of a proposed biosimilar trastuzumab in the US.

These shark antibodies are considered to have immediate and highly disease-specific potential for the diagnosis and treatment of Alzheimer’s disease.

First of five planned clinical trials to test ZPIV vaccine.

Merger with sister company, C-Tech Electronics Ltd, to form a new vertically integrated manufacturing company.

Allows adult patients with advanced melanoma to receive first-line treatment with the potentially life-extending combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) on the NHS in Scotland.

Biogen is preparing for the potential launch of Spinraza in the US possibly as early as the end of 2016.

New research has raised the possibility of minimising the side effects of treatment for patients with autoimmune diseases, such as multiple sclerosis and inflammatory bowel disease.

Conference welcomes pulmonary and nasal drug delivery experts from all over the world.

Merck is the first multinational enterprise to dedicate a large-scale green-field investment (€170 million) to the production of pharmaceuticals on China’s Essential Drug List.

Patent will cover a method of treating a subject having a viral infection caused by an influenza virus with neuraminidase inhibitors in combination with MEK inhibitors.

First early access scheme for breakthrough immunotherapy in blood cancer.

Provides access for patients and streamlined reimbursement.

Filing includes analytical, functional and pre-clinical data, and results from the pharmacokinetics and confirmatory efficacy/safety global clinical trial in Type 2 diabetes patients comparing Mylan's and Biocon's Insulin glargine with Lantus.

Four dosage strengths of quetiapine fumarate extended release tablets being distributed.

TraceLink to present on global serialisation strategies at Pharmaceutical Serialisation & Traceability 2016.

Is the first breast cancer treatment to be recommended by NICE in nearly a decade.

As well as increasing output, the company is also investing in new technologies, including flow chemistry, chromatography and hydrogenation capabilities.

Bococizumab deemed unlikely to provide value to patients, physicians, or shareholders.

Trial showed LEE011 plus letrozole reduced the risk of progression or death by 44% over letrozole alone.

10 events to drive India’s rapid pharma growth predicted to reach $55bn by 2020.

Europe to be a key market for the company's phage-based therapies to treat bacterial infections in patients with unmet medical needs.

Amendments to the national immunization schedules of the US and the UK, the expansion of egg-based quadrivalent seasonal influenza vaccines across Germany, Italy, France, and Spain, and the transition from egg-based to cell culture-based vaccines will ...

MorphaBond is an abuse-deterrent formulation of extended release morphine using physical and chemical barriers, without the use of aversive agents or opioid antagonists.

Acquisition adds global rights to highly differentiated compounds to treat multi-factorial elements of NASH.

Access for Canadian women remains in jeopardy despite mounting evidence of significant clinical benefits of Lynparza.

Gleevec recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx as Best Biotechnology Product.

If approved, avelumab, an investigational anti-PD-L1 IgG1, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma.

Collaboration provides a comprehensive platform for data management, analysis and compound design in drug discovery.

A new delivery system for the nonly FDA-approved treatment to help patients produce more of their own tears.

Acquisition would expand Astellas' oncology pipeline with antibody in late-stage.

Products include an innovative Tool Management System and a new patented elliptical punch head form designed to increase dwell time on an existing table press without the need for time-consuming and expensive modifications.

The injection of capital follows an impressive year of growth for the company.

Deficiencies identified during a routine good manufacturing practice inspection of the Sanofi Le Trait facility in France where sarilumab is filled and finished.

Award recognizes BMS for driving innovation in immuno-oncology.

New studies support flexible dosing and co-administration with flu vaccine.

Acquisition expands Allergan's gastroenterology pipeline.

The seminars discuss tablet design, tool material selection, tool features and configuration, tooling maintenance and lifecycle management.

Gamlen Tableting to demonstrate its new manufacturability protocol at AAPS.

First dedicated small-molecule manufacturing line to be constructed in Visp, Switzerland.

The three research organizations have a history of flavivirus vaccine collaboration.

Pharmapack Awards 2017 closing: Calling all pharma packaging and drug delivery innovators.

NIH-funded study suggests patch is safe, convenient mode of treatment.

Phase III study established equivalence in efficacy and similar safety profile between BI 695501 and Humira (adalimumab) in patients with active rheumatoid arthritis.

New solutions for the packaging process.

Programs include a systematic approach to drug repurposing and data-driven, proactive chronic disease management - both fueled by the IBM Watson Health Cloud.

Provides pan-European availability of widely used and much needed oral liquid version clobazam tablets.

Investment reflects Amgen's commitment to serving patients by driving innovation and sustainable healthcare through technology discovery.

Results demonstrate encouraging response rate in an expanded population of heavily pre-treated classical Hodgkin lymphoma patients.

Approval is for first-line treatment of patients whose tumours have high PD-L1 expression with no EGFR or ALK genomic tumour aberrations.

Executives emphasised the importance of being first to market, two distinct outsourcing strategies, with biopharm and HPAPIs segments reporting strong growth.

New treatment elicits two-pronged immune response that destroys tumors in mice.

Company to invest $34 million in facility extension to add a new 2 x 2,000 L single-use bioreactor system and laboratory space.

The US will not only remain the largest major market for MDD drugs, but will extend its lead over other countries, says GlobalData.

Under ideal circumstances, any B2C industry, pharmaceutical or otherwise, wants all his packaging to be procured from one place. Sourcing the primary packaging viz. laminate tubes and the secondary packaging viz. cartons; can help in better color match...

Data demonstrate improvement in radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer who were treated with enzalutamide compared to patients who were treated with bicalutamide.

Keytruda is the first immunotherapy to show improved overall survival compared with chemotherapy in urothelial cancer.

Inflectra will be the first biosimilar monoclonal antibody (mAb) to be available in the US.

Keynote speaker says traditional monolayer cell culture models used to study tumour chemoresistance have proven to be woefully inadequate.

Top-line results across more than 1,250 moderate to very severe COPD patients confirmed that both Phase III studies met their primary efficacy endpoint.

Propeller Health has developed a digital platform that integrates information from multiple sources and uses machine intelligence to recommend an optimal path therapy for individuals who suffer from COPD, asthma and other respiratory diseases.

Get to know SILFAR® S 184 - a silicone antifoam agent developed specifically for the pharmaceutical sector. Typical applications for SILFAR® S 184 include antiflatulent, antacid and fermented preparations. visit www.wacker.com

Collaboration will focus on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets.

Will lead the company’s ongoing efforts to anticipate and act upon industry trends and technologies that may affect study sponsors, clinical sites, and patients, and to inform the development and delivery of current and future clinical supply services.

Sterinova to specialise in developing and manufacturing sterile ready-to-use injectable products.

The new facilities includes dedicated cell development suites and new robotic platforms for process automation.

The subscription deal, which is valued at a minimum of £500,000, provides partner access to Horizon's engineered cell lines.

First and only anti-PDL1 cancer immunotherapy approved by the FDA for metastatic non-small cell lung cancer.

The new clinical trial research grants total more then $23 million over the next 4 years.

Substantial rise can be attributed to increased drug consumption, caused by a rising disease burden, and government initiatives in the public healthcare sector.

Pre-filled syringes to be produced at Brussels, Belgium facility.

Brain cells that provide structural support also influence feeding behavior, study shows.

New database provides access to oncology studies in an effort to speed medicines to patients.

Extension of manufacturing plant will help meet worldwide demand for fertility and growth hormone disorder treatments.

Facilities chosen for their contributions to anti-infectives and vaccines.

Will become the largest GLP bioanalysis laboratory of its kind in the Nordic countries.

The addition of a roller compactor support's the company's recent capability extensions made in spray drying, Xcelodose technology, bi-layer tablets production and high-speed encapsulation.

Prize awarded for development of novel synthesis of Dronedarone intermediate.

The newest addition for 2017, the Pharmapack Start-up Hub, is designed to let innovative young pharma firms benefit from valuable networking and learning opportunities.

Postnova Analytics to host free 1-day seminar on advanced separation techniques.

Will include sharing information on industry trends and tooling expertise.

Includes Merck’s type 2 diabetes treatment portfolio, in patients with renal impairment.

Includes an oral presentation looking at the effect of prior treatment with tumour necrosis factor inhibitors on efficacy endpoints.

Can be used in a wide range of applications in upstream, downstream, and formulation and filling.

Marketing authorization given for the treatment of moderate to severe fullness under the chin.

TNT009 is currently in clinical development for the treatment of autoimmune hemolytic anemia, including Cold Agglutinin Disease (CAD), a form of autoimmune hemolytic anemia.

Cerbios will provide highly cytotoxic drug payloads and conjugation services for manufacture of ADC drug substance whereas Oncotec will provide sterile filling and lyophilization of cytotoxic active ingredients for ADCs.

Trial shows rigorous clinical research feasible during a public health emergency.

Company's continued expansion allows it to further improve the transition of drug candidates from the discovery medicinal chemistry space through to formal regulatory based drug product development.

The studies have the potential to reveal novel insights for previously unknown autophagy signalling components, which could suggest rapid and innovative starting points for new drug treatments.

Approximately 30 members of staff will lose their job.

This substantial growth will primarily be driven by the growth of atypical antipsychotics, along with the increasing global diagnosed prevalence of MDD, and the potential introduction of six late-stage pipeline products.

Collaboration supports GLP toxicity studies and initiation of clinical development for treatment of Progressive Multifocal Leukoencephalopathy.

Is the first patent issued protecting the composition and method of use for Metablok, the company's drug candidate targeting inflammation, sepsis and cancer metastasis.

Application seeks to expand Avycaz label to include Phase III clinical data for the treatment of complicated urinary tract infections.

The new formulation will be offered in 4,000 lipase units capsule.

Grant established by Merck recognizes pioneering research in personalized treatment of solid tumours.

Data were presented at the 2016 European Society for Medical Oncology Congress.

The UAE is quickly gaining popularity as a medical tourism destination due to its low costs, English-speaking medical staff, and virtually non-existent queues for treatment.

The terms of the settlement do not provide for any finding of wrongdoing on the part of Mylan Inc. or any of its affiliated entities or personnel.

Funding will allow the company to advance its research projects and move closer towards its goal of evaluating the efficacy of muco-regulatory drugs in patients.

Nyaditum resae targets to reduce the risk of developing the disease in people who carry the tuberculosis bacteria and those at risk of infection.

Will provide the central technical base for laboratory operations associated with the development and validation of manufacturing processes and analytical methods for the company’s products.

Sanofi Genzyme expects to submit a supplemental Biologics License Application to the FDA next year.

Company to start manufacturing in Brazil.

Cadence Acoustic Separator system is a novel single-use solution for the clarification of cell culture bioprocess fluids.

Although the market has recently been hit by the patent expirations of a number of the leading gastrointestinal products, the approval of new drugs, as well as rising prevalence, are expected to drive considerable growth. says GBI Research.

Eight new product lines and a fully integrated manufacturing and R&D site to transfer to Elanco, adding to its growing companion animal business.

Transaction is part of the European Commission’s anti-trust divestiture requirements arising from Teva’s acquisition of Allergan’s generics business.

Shire pleased with the decision and will continue to vigorously defend its patents.

Enables fully scalable, continuous multicolumn chromatography

New report compares the thermal performance and advantages of vacuum jacketed versus non-vacuum jacketed reaction vessels.